688373 盟科药业-U
已收盘 07-14 15:00:02
资讯
新帖
简况
每周股票复盘：盟科药业（688373）证券事务代表因个人原因辞职
证券之星 · 07-12 02:10
每周股票复盘：盟科药业（688373）证券事务代表因个人原因辞职
盟科药业（688373）披露证券事务代表辞职公告，7月7日股价下跌3.28%
证券之星 · 07-07
盟科药业（688373）披露证券事务代表辞职公告，7月7日股价下跌3.28%
股市必读：盟科药业（688373）7月2日董秘有最新回复
证券之星 · 07-03
股市必读：盟科药业（688373）7月2日董秘有最新回复
盟科药业（688373）5059.05万股限售股将于7月1日解禁，占总股本7.71%
证券之星 · 07-01
盟科药业（688373）5059.05万股限售股将于7月1日解禁，占总股本7.71%
每周股票复盘：盟科药业（688373）部分限售股7月1日解禁
证券之星 · 06-28
每周股票复盘：盟科药业（688373）部分限售股7月1日解禁
盟科药业（688373）披露首次公开发行部分限售股上市流通公告，6月22日股价下跌3.46%
证券之星 · 06-22
盟科药业（688373）披露首次公开发行部分限售股上市流通公告，6月22日股价下跌3.46%
每周股票复盘：盟科药业（688373）2025年年度股东会决议公告
证券之星 · 06-07
每周股票复盘：盟科药业（688373）2025年年度股东会决议公告
盟科药业（688373）披露2025年年度股东会决议公告，6月2日股价下跌1.67%
证券之星 · 06-02
盟科药业（688373）披露2025年年度股东会决议公告，6月2日股价下跌1.67%
每周股票复盘：盟科药业（688373）2025年营收1.42亿元
证券之星 · 05-31
每周股票复盘：盟科药业（688373）2025年营收1.42亿元
A股公告精选 | 中芯国际(00981)、沪硅产业(688126.SH)等近期遭国家大基金减持
智通财经网 · 05-28
A股公告精选 | 中芯国际(00981)、沪硅产业(688126.SH)等近期遭国家大基金减持
盟科药业（688373）披露2025年年度股东会会议资料，5月26日股价下跌2.43%
证券之星 · 05-26
盟科药业（688373）披露2025年年度股东会会议资料，5月26日股价下跌2.43%
盟科药业跌3.25% 2022年上市即巅峰募10.6亿元
中金财经 · 05-13
盟科药业跌3.25% 2022年上市即巅峰募10.6亿元
股市必读：盟科药业（688373）5月12日披露最新机构调研信息
证券之星 · 05-13
股市必读：盟科药业（688373）5月12日披露最新机构调研信息
每周股票复盘：盟科药业（688373）股东减持计划期满未实施
证券之星 · 05-10
每周股票复盘：盟科药业（688373）股东减持计划期满未实施
股市必读：4月30日盟科药业发布公告，股东减持656.23万股
证券之星 · 05-06
股市必读：4月30日盟科药业发布公告，股东减持656.23万股
每周股票复盘：盟科药业（688373）股东减持656.23万股触及1%变动
证券之星 · 05-02
每周股票复盘：盟科药业（688373）股东减持656.23万股触及1%变动
4月30日盟科药业发布公告，股东减持656.23万股
证券之星 · 04-30
4月30日盟科药业发布公告，股东减持656.23万股
盟科药业(688373)3月31日股东户数1.7万户，较上期增加3.55%
证券之星 · 04-29
盟科药业(688373)3月31日股东户数1.7万户，较上期增加3.55%
图解盟科药业一季报：第一季度单季净利润同比增长65.19%
证券之星 · 04-29
图解盟科药业一季报：第一季度单季净利润同比增长65.19%
每周股票复盘：盟科药业（688373）完成注册资本变更
证券之星 · 04-26
每周股票复盘：盟科药业（688373）完成注册资本变更
加载更多
公司概况
公司名称：
上海盟科药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-05
主营业务：
上海盟科药业股份有限公司的主营业务是以小分子化药研发为核心，发现、开发和商业化未满足临床需求的创新药物。公司的主要产品是康替唑胺片。
发行价格：
8.16
{"stockData":{"symbol":"688373","market":"SH","secType":"STK","nameCN":"盟科药业-U","latestPrice":5.2,"timestamp":1784012402000,"preClose":5.05,"halted":0,"volume":20945325,"delay":0,"changeRate":0.0297,"floatShares":656000000,"shares":656000000,"eps":-0.307,"marketStatus":"已收盘","change":0.15,"latestTime":"07-14 15:00:02","open":5.05,"high":5.26,"low":4.88,"amount":107000000,"amplitude":0.0752,"askPrice":5.21,"askSize":855,"bidPrice":5.2,"bidSize":144,"shortable":0,"etf":0,"ttmEps":-0.307,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784079000000},"marketStatusCode":5,"adr":0,"adjPreClose":5.05,"symbolType":"stock_kcb","openAndCloseTimeList":[[1783992600000,1783999800000],[1784005200000,1784012400000]],"highLimit":5.56,"lowLimit":4.55,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":656228380,"isCdr":false,"pbRate":18.76,"roa":"--","roe":"--","epsLYR":-0.37,"committee":0.04386,"marketValue":3412000000,"turnoverRate":0.0319,"status":0,"afterMarket":{"amount":0,"volume":0,"close":5.2,"buyVolume":2291,"sellVolume":0,"time":1784014437746,"indexStatus":"已收盘 07-14 15:30:00","preClose":5.05},"floatMarketCap":3412000000},"requestUrl":"/m/hq/s/688373","defaultTab":"news","newsList":[{"id":"2650545541","title":"每周股票复盘：盟科药业（688373）证券事务代表因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2650545541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650545541?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:10","pubTimestamp":1783793418,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，盟科药业报收于5.19元，较上周的5.11元上涨1.57%。本周，盟科药业7月10日盘中最高价报5.37元。本周关注点公司公告汇总：证券事务代表奉竹女士因个人原因辞职，辞任自送达董事会之日起生效。公司公告汇总上海盟科药业股份有限公司董事会近日收到证券事务代表奉竹女士的辞职报告。公司董事会对奉竹女士在任职期间的贡献表示感谢，并将依据相关规定尽快聘任新的证券事务代表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","161027","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649431935","title":"盟科药业（688373）披露证券事务代表辞职公告，7月7日股价下跌3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649431935","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649431935?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:29","pubTimestamp":1783434557,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，盟科药业报收于5.02元，较前一交易日下跌3.28%，最新总市值为32.94亿元。近日，上海盟科药业股份有限公司发布《关于证券事务代表辞职的公告》。公告显示，公司董事会收到证券事务代表奉竹女士的辞职报告，因个人原因，奉竹女士申请辞去公司证券事务代表职务，辞职后不再担任公司任何职务，其辞任自送达董事会之日起生效。公司董事会对奉竹女士在任职期间的贡献表示感谢，并将依据相关规定尽快聘任新的证券事务代表。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700041729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648870466","title":"股市必读：盟科药业（688373）7月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648870466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648870466?lang=zh_cn&edition=full","pubTime":"2026-07-03 03:03","pubTimestamp":1783018993,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，盟科药业报收于4.98元，上涨1.01%，换手率4.49%，成交量29.48万手，成交额1.48亿元。董秘最新回复投资者： 请问贵公司投入了这么多研发费用，净利润却惨不忍睹，是否光有投入没有产出？公司属于创新药企业，药物研发从投入到临床试验需要经历完整的循证医学论证及相关审批，药物研发最终经批准上市并商业化后才能产生利润。当日关注点交易信息汇总：7月2日主力资金净流入544.32万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300002144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648134593","title":"盟科药业（688373）5059.05万股限售股将于7月1日解禁，占总股本7.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648134593","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648134593?lang=zh_cn&edition=full","pubTime":"2026-07-01 08:03","pubTimestamp":1782864180,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，盟科药业于7月1日将有5059.05万股限售股份解禁，为公司首发原股东限售股份,追加承诺限售股份上市流通，占公司总股本7.71%。最近一年内，该股累计解禁2.39亿股，占总股本的36.42%。盟科药业主营业务：以治疗感染性疾病为核心,拥有全球自主知识产权和国际竞争力的创新药企业,致力于发现、开发和商业化针对未满足临床需求的创新药物。本文数据来源于盟科药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100009445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646316688","title":"每周股票复盘：盟科药业（688373）部分限售股7月1日解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2646316688","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646316688?lang=zh_cn&edition=full","pubTime":"2026-06-28 04:18","pubTimestamp":1782591492,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，盟科药业报收于4.21元，较上周的4.63元下跌9.07%。本周，盟科药业6月23日盘中最高价报4.83元。盟科药业当前最新总市值27.63亿元，在化学制药板块市值排名126/150，在两市A股市值排名4400/5206。公司公告汇总上海盟科药业股份有限公司首次公开发行部分限售股共计50,590,485股，将于2026年7月1日上市流通，占公司总股本的7.71%。保荐机构中国国际金融股份有限公司对本次解禁无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073068","title":"盟科药业（688373）披露首次公开发行部分限售股上市流通公告，6月22日股价下跌3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073068","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645073068?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:47","pubTimestamp":1782139636,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，盟科药业报收于4.47元，较前一交易日下跌3.46%，最新总市值为29.33亿元。该股当日开盘4.59元，最高4.64元，最低4.3元，成交额达8451.74万元，换手率为3.17%。近日，盟科药业发布《首次公开发行部分限售股上市流通公告》。公告显示，公司首次公开发行部分限售股将于2026年7月1日上市流通，本次上市流通数量为50,590,485股，占公司总股本的7.71%。公司股本因限制性股票激励计划有所增加，保荐机构对本次限售股解禁无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200039147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127649","title":"每周股票复盘：盟科药业（688373）2025年年度股东会决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127649","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127649?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:25","pubTimestamp":1780770312,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，盟科药业报收于4.59元，较上周的4.68元下跌1.92%。本周，盟科药业6月1日盘中最高价报4.84元。本周关注点公司公告汇总：盟科药业2025年年度股东会审议通过利润分配方案等四项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294136","title":"盟科药业（688373）披露2025年年度股东会决议公告，6月2日股价下跌1.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640294136?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:45","pubTimestamp":1780411518,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，盟科药业报收于4.7元，较前一交易日下跌1.67%，最新总市值为30.84亿元。该股当日开盘4.79元，最高4.79元，最低4.62元，成交额达4331.41万元，换手率为1.53%。近日，盟科药业发布《2025年年度股东会决议公告》。公告显示，公司于2026年6月2日召开2025年年度股东会，会议由董事会召集，董事长ZHENGYU YUAN（袁征宇）主持，采用现场与网络投票结合方式召开。中小投资者对相关议案进行了单独计票，关联股东对涉及议案已回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200047581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639760448","title":"每周股票复盘：盟科药业（688373）2025年营收1.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2639760448","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639760448?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:48","pubTimestamp":1780170492,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，盟科药业报收于4.68元，较上周的5.02元下跌6.77%。本周，盟科药业5月25日盘中最高价报5.08元。盟科药业当前最新总市值30.71亿元，在化学制药板块市值排名128/150，在两市A股市值排名4455/5207。报告期内，公司实现营业收入14,177.27万元，同比增长8.83%；康替唑胺片覆盖703家医院；MRX-4、MRX-5等在研项目推进顺利。2025年度不进行利润分配，也不进行资本公积转增股本。独立董事津贴标准为12万元/年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693315","title":"A股公告精选 | 中芯国际(00981)、沪硅产业(688126.SH)等近期遭国家大基金减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693315","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638693315?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:14","pubTimestamp":1779970451,"startTime":"0","endTime":"0","summary":"据港交所文件披露，国家集成电路产业投资基金股份有限公司对中芯国际的多头持仓比例于2026年5月26日从8.08%降至7.99%。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260528/20260528201402_31661.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260528/20260528201402_31661.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0064","BK0070","BK1163","603011","BK0071","688443","LU2476274720.SGD","BK0022","BK0214","06809","BK0028","BK0229","BK0061","BK0084","BK0139","LU2495084118.USD","BK0187","LU1770034418.SGD","LU1251922891.USD","BK0076","BK0152","BK0183","BK0242","601958","LU0456842615.SGD","LU2039709279.SGD","000691","BK0196","LU2778985437.USD","BK0077","BK0012","BK0102","BK0188","BK1607","00981","BK0239","688373","BK0231","LU2476274308.USD","688126","BK0000","300941","LU1997244956.HKD","LU1997245177.USD","600029","BK1526","BK0280","BK0010","01055","688008","BK1610","BK0177","BK0164","BK1614","LU1997245094.SGD","BK0182","LU1303224171.USD","600330","BK0006","BK0259","LU1719994722.HKD","688981","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638411543","title":"盟科药业（688373）披露2025年年度股东会会议资料，5月26日股价下跌2.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638411543","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638411543?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:38","pubTimestamp":1779806297,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，盟科药业报收于4.81元，较前一交易日下跌2.43%，最新总市值为31.56亿元。该股当日开盘4.91元，最高4.97元，最低4.74元，成交额达5790.71万元，换手率为1.98%。近日，上海盟科药业股份有限公司披露《2025年年度股东会会议资料》。公告显示，本次股东会将审议《公司2025年度董事会工作报告》《公司2025年度利润分配方案》《公司董事2026年薪酬方案》及《董事和高级管理人员薪酬管理制度》。2025年度不进行利润分配，也不进行资本公积转增股本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635720949","title":"盟科药业跌3.25% 2022年上市即巅峰募10.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635720949","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635720949?lang=zh_cn&edition=full","pubTime":"2026-05-13 15:56","pubTimestamp":1778658976,"startTime":"0","endTime":"0","summary":"中国经济网北京5月13日讯 盟科药业 今日股价下跌，截至收盘，该股报5.65元，跌幅3.25%。 盟科药业于2022年8月5日在上交所科创板上市，公开发行股份数为13,000.00万股，发行价格为8.16元/股，保荐机构中国国际金融股份有限公司，保荐代表人为陶泽旻、马致远。 上市首日，盟科药业盘中最高报14.20元，为该股上市以来最高价。 盟科药业首次公开发行股票的发行费用总额为10,107.21万元，其中，保荐及承销费用7,902.96万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260513/32220632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688373","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635168249","title":"股市必读：盟科药业（688373）5月12日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2635168249","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635168249?lang=zh_cn&edition=full","pubTime":"2026-05-13 01:15","pubTimestamp":1778606111,"startTime":"0","endTime":"0","summary":"截至2026年5月12日收盘，盟科药业报收于5.84元，下跌2.67%，换手率1.89%，成交量11.42万手，成交额6714.11万元。具体以公司披露的公告为准。答：截至2025年度末，康替唑胺片已覆盖全国703家医院，实现正式准入及批量临采医院已达220家。自2021年该产品上市以来，公司营业收入增长明显，2021年至2025年分别实现0.08亿元、0.48亿元、0.91亿元、1.30亿元、1.42亿元，呈现整体增长态势。2025年12月，康替唑胺片成功以原价续约国家医保目录，协议期覆盖至2027年底。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300001612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634411777","title":"每周股票复盘：盟科药业（688373）股东减持计划期满未实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2634411777","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634411777?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:00","pubTimestamp":1778349638,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，盟科药业报收于5.89元，较上周的6.02元下跌2.16%。本周，盟科药业5月7日盘中最高价报6.09元。2026年1月15日，公司披露减持计划，JSR与GP TMT拟合计减持不超过19,686,851股，即不超过公司总股本的3%，减持期间为2026年2月5日至5月4日。截至2026年5月4日，JSR与GP TMT未通过集中竞价或大宗交易方式减持公司任何股份，本次减持计划时间届满且未实施减持。减持完成后，JSR仍持有28,591,294股，GP TMT仍持有17,299,247股，合计持股比例仍为6.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633784399","title":"股市必读：4月30日盟科药业发布公告，股东减持656.23万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633784399","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633784399?lang=zh_cn&edition=full","pubTime":"2026-05-06 06:25","pubTimestamp":1778019913,"startTime":"0","endTime":"0","summary":"来自股本股东变化：股东Best Idea International Limited在减持期间合计减持656.23万股，持股比例由7.91%降至6.91%。股本股东变化股东增减持4月30日盟科药业发布公告《盟科药业:上海盟科药业股份有限公司关于股东减持计划时间届满暨减持股份结果且权益变动触及1%刻度的公告》，其股东Best Idea International Limited于2026年2月5日至2026年4月30日间合计减持656.23万股，占公司目前总股本的1.0%，变动期间该股股价下跌3.83%，截止4月30日收盘报6.02元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600004283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632625965","title":"每周股票复盘：盟科药业（688373）股东减持656.23万股触及1%变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2632625965","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632625965?lang=zh_cn&edition=full","pubTime":"2026-05-02 07:03","pubTimestamp":1777676594,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，盟科药业报收于6.02元，较上周的5.91元上涨1.86%。本周关注点股本股东变化：股东Best Idea International Limited减持656.23万股，持股比例下降1.0%。股本股东变化股东增减持4月30日，盟科药业公告显示，股东Best Idea International Limited在2026年2月5日至4月30日期间累计减持656.23万股，占公司总股本的1.0%，减持价格区间为5.85至6.41元/股，总金额40,142,116.09元。股东户数变动截至2026年3月31日，公司股东户数为1.7万户，较2月28日增加583户，增幅3.55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631142630","title":"4月30日盟科药业发布公告，股东减持656.23万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631142630","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631142630?lang=zh_cn&edition=full","pubTime":"2026-04-30 21:02","pubTimestamp":1777554171,"startTime":"0","endTime":"0","summary":"证券之星消息，4月30日盟科药业发布公告《盟科药业:上海盟科药业股份有限公司关于股东减持计划时间届满暨减持股份结果且权益变动触及1%刻度的公告》，其股东Best Idea International Limited于2026年2月5日至2026年4月30日间合计减持656.23万股，占公司目前总股本的1.0%，变动期间该股股价下跌3.83%，截止4月30日收盘报6.02元。股东增减持详情见下表：根据盟科药业2026年一季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000066373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631596358","title":"盟科药业(688373)3月31日股东户数1.7万户，较上期增加3.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596358","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596358?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:43","pubTimestamp":1777455823,"startTime":"0","endTime":"0","summary":"证券之星消息，近日盟科药业披露，截至2026年3月31日公司股东户数为1.7万户，较2月28日增加583.0户，增幅为3.55%。在化学制药行业个股中，盟科药业股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年2月28日至2026年3月31日，盟科药业区间跌幅为2.37%，在此期间股东户数增加583.0户，增幅为3.55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900055457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631753914","title":"图解盟科药业一季报：第一季度单季净利润同比增长65.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631753914","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631753914?lang=zh_cn&edition=full","pubTime":"2026-04-29 04:54","pubTimestamp":1777409641,"startTime":"0","endTime":"0","summary":"证券之星消息，盟科药业2026年一季报显示，一季度公司主营收入4205.97万元，同比上升26.62%；归母净利润-2145.36万元，同比上升65.19%；扣非净利润-2328.82万元，同比上升63.21%；负债率73.15%，财务费用365.38万元，毛利率85.6%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900010686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630258802","title":"每周股票复盘：盟科药业（688373）完成注册资本变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2630258802","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630258802?lang=zh_cn&edition=full","pubTime":"2026-04-26 05:24","pubTimestamp":1777152255,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，盟科药业报收于5.91元，较上周的6.21元下跌4.83%。本周，盟科药业4月20日盘中最高价报6.33元。本周关注点公司公告汇总：盟科药业完成注册资本变更，新注册资本为65622.8380万元。公司公告汇总上海盟科药业股份有限公司于2026年3月26日召开第二届董事会第二十六次会议，审议通过变更公司注册资本、修订《公司章程》并办理工商变更登记的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600002344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784019228760,"stockEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":0.0954},{"period":"3month","weight":-0.1894},{"period":"6month","weight":-0.2519},{"period":"1year","weight":-0.2957},{"period":"ytd","weight":-0.1639}],"compareEarnings":[{"period":"1week","weight":-0.0315},{"period":"1month","weight":-0.0292},{"period":"3month","weight":-0.028},{"period":"6month","weight":-0.0515},{"period":"1year","weight":0.115},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海盟科药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17006人(较上一季度增加3.55%)","perCapita":"38588股","listingDate":"2022-08-05","address":"上海市浦东新区中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101、2幢","registeredCapital":"65622万元","survey":" 上海盟科药业股份有限公司的主营业务是以小分子化药研发为核心，发现、开发和商业化未满足临床需求的创新药物。公司的主要产品是康替唑胺片。","listedPrice":8.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"盟科药业-U(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供盟科药业-U(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"盟科药业-U,688373,盟科药业-U股票,盟科药业-U股票老虎,盟科药业-U股票老虎国际,盟科药业-U行情,盟科药业-U股票行情,盟科药业-U股价,盟科药业-U股市,盟科药业-U股票价格,盟科药业-U股票交易,盟科药业-U股票购买,盟科药业-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"盟科药业-U(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供盟科药业-U(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}